Education
About Us
Working with TipRanks
Follow Us
Bioxcel Therapeutics (BTAI)
:BTAI
BTAI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.29 - $48.72
Previous CloseN/A
Volume1.10M
Average Volume (3M)518.37K
Market Cap
$9.98M
Enterprise Value$91.27M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.13
Next Earnings
May 12, 2025EPS Estimate
-2.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-25.91
Shares Outstanding5,486,038
10 Day Avg. Volume111,195
30 Day Avg. Volume518,365
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.18
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market Cap9.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit40.28
Enterprise Value/Ebitda-1.63
Forecast
1Y Price Target
$38.00Price Target Upside2083.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Bioxcel Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe initiation of the Phase 3 SERENITY At-Home study for Igalmi is seen as a positive development, potentially driving increased revenue.
FDA InspectionBTAI shares are trading +150% after announcing that the FDA has concluded the site inspection for one of the sites in the TRANQUILITY II phase 3 trial, with voluntary action indicated.
Financial ResilienceThe company's ability to consistently renegotiate financial terms with creditors is seen as a positive sign of resilience.
Bears Say
Financial ConcernsThe company's financial situation is a major concern due to limited cash and the need to raise additional funds to meet debt covenants.
Sales PerformanceBTAI reported much lower than expected Igalmi sales, which missed consensus estimates significantly.
Stock Price And DilutionThe proposed follow-on offering is necessary but will be highly dilutive due to the current depressed stock price.
---
Ownership Overview
13.61% Insiders
5.78% Mutual Funds
0.10% Other Institutional Investors
79.18% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BTAI FAQ
What was Bioxcel Therapeutics’s price range in the past 12 months?
Bioxcel Therapeutics lowest stock price was $1.29 and its highest was $48.72 in the past 12 months.
What is Bioxcel Therapeutics’s market cap?
Bioxcel Therapeutics’s market cap is $9.98M.
When is Bioxcel Therapeutics’s upcoming earnings report date?
Bioxcel Therapeutics’s upcoming earnings report date is May 12, 2025 which is in 24 days.
How were Bioxcel Therapeutics’s earnings last quarter?
Bioxcel Therapeutics released its earnings results on Mar 27, 2025. The company reported -$3.57 earnings per share for the quarter, beating the consensus estimate of -$6.044 by $2.474.
Is Bioxcel Therapeutics overvalued?
According to Wall Street analysts Bioxcel Therapeutics’s price is currently Undervalued.
Does Bioxcel Therapeutics pay dividends?
Bioxcel Therapeutics does not currently pay dividends.
What is Bioxcel Therapeutics’s EPS estimate?
Bioxcel Therapeutics’s EPS estimate is -2.13.
How many shares outstanding does Bioxcel Therapeutics have?
Bioxcel Therapeutics has 5,486,038 shares outstanding.
What happened to Bioxcel Therapeutics’s price movement after its last earnings report?
Bioxcel Therapeutics reported an EPS of -$3.57 in its last earnings report, beating expectations of -$6.044. Following the earnings report the stock price went up 5.963%.
Which hedge fund is a major shareholder of Bioxcel Therapeutics?
Among the largest hedge funds holding Bioxcel Therapeutics’s share is Driehaus Capital Management LLC. It holds Bioxcel Therapeutics’s shares valued at 0.
---
Bioxcel Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.00 (2083.91% Upside)
$38.00 (2083.91% Upside)
Blogger Sentiment
Bullish
BTAI Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 2.7%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-95.80%
12-Months-Change
Fundamentals
Return on Equity
82.91%
Trailing 12-Months
Asset Growth
-47.98%
Trailing 12-Months
Company Description
Bioxcel Therapeutics
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
---
BTAI Stock 12 Month Forecast
Average Price Target
$38.00
▲(2083.91% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Corcept Therapeutics
―
Intra-Cellular Therapies
―
SAGE Therapeutics
―
Axsome Therapeutics
―
Best Analysts Covering BTAI
1 Year
1 Year Success Rate
12/40 ratings generated profit
1 Year Average Return
+32.81%
reiterated a buy rating 4 months ago
Copying Sumant Kulkarni's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of +32.81% per trade.
---